Literature DB >> 3275487

Tumor markers in pleural effusion diagnosis.

S Tamura1, T Nishigaki, Y Moriwaki, H Fujioka, T Nakano, J Fujii, T Yamamoto, K Nabeshima, T Hada, K Higashino.   

Abstract

In order to discriminate between malignant and benign effusions, the values of carcinoembryonic antigen (CEA), ferritin, beta2-microglobulin (BMG), acid-soluble glycoprotein (ASP), tissue polypeptide antigen (TPA), adenosine deaminase (ADA), and immunosuppressive acidic protein (IAP) were measured in the pleural fluid of 54 patients with lung cancer, 20 with malignancies other than lung cancer, 18 with tuberculous pleurisy, and 22 with benign diseases other than tuberculosis. CEA levels in malignant effusions were significantly higher than those in benign effusions. At a cutoff level of 5 ng/ml, 68% of the patients with lung cancer and 44% of the patients with other malignancies showed elevated pleural fluid CEA levels. In 13 lung cancer cases with negative pleural fluid cytology, nine cases had elevated pleural fluid CEA levels. The mean pleural fluid BMG level of patients with benign diseases was significantly higher than that of patients with malignant diseases, but there was a marked overlap between those with malignant and benign diseases. No significant differences were found in the pleural fluid ferritin, ASP, TPA, and IAP levels between malignant and benign conditions. ASP and IAP pleural fluid levels showed significant correlations with the pleural fluid C-reactive protein (CRP) concentrations suggesting that they also reflect inflammatory activity. The mean ADA activity in tuberculous effusion was significantly higher than that resulting from other causes of pleural effusion.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3275487     DOI: 10.1002/1097-0142(19880115)61:2<298::aid-cncr2820610219>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Carcinoembryonic antigen, tissue polypeptide antigen and neuron-specific enolase pleural levels used to classify small-cell and non-small-cell lung cancer patients by discriminant analysis.

Authors:  G Paone; G De Angelis; S Greco; F Fiorucci; A Bisetti; F Ameglio
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  Diagnostic tests in pleural effusion--an update.

Authors:  N Berkman; M R Kramer
Journal:  Postgrad Med J       Date:  1993-01       Impact factor: 2.401

3.  Tumor-associated antigens in effusions of malignant and benign origin.

Authors:  A Ammon; H Eiffert; S Reil; J H Beyer; M Droese; W Hiddemann
Journal:  Clin Investig       Date:  1993-06

4.  Diagnostic value of serum tumor markers in skeletal metastasis of carcinomas.

Authors:  M Chigira; T Shinozaki
Journal:  Arch Orthop Trauma Surg       Date:  1990       Impact factor: 3.067

5.  Reactive oxygen metabolites can be used to differentiate malignant and non-malignant pleural efffusions.

Authors:  Ufuk Cobanoglu; Fuat Sayir; Duygu Mergan
Journal:  Ann Thorac Med       Date:  2010-07       Impact factor: 2.219

6.  Endostatin levels in exudative pleural effusions.

Authors:  M Sumi; K Kagohashi; H Satoh; H Ishikawa; Y Funayama; K Sekizawa
Journal:  Lung       Date:  2003 Nov-Dec       Impact factor: 2.584

7.  Prognostic value of serial serum interleukin-6 level estimation in patients with lung cancer: a preliminary report.

Authors:  A Wojciechowska-Lacka; E Adamiak; G Stryczynska; J K Lacki
Journal:  Yale J Biol Med       Date:  1997 Mar-Apr

8.  Diagnostic value of ex vivo pleural fluid interferon-gamma versus adapted whole-blood quantiferon-TB gold in tube assays in tuberculous pleural effusion.

Authors:  Eman N Eldin; Asmaa Omar; Mahmoud Khairy; Adel H M Mekawy; Maha K Ghanem
Journal:  Ann Thorac Med       Date:  2012-10       Impact factor: 2.219

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.